Technetium (99mTc) arcitumomab is a monoclonal antibody-based imaging agent used in nuclear medicine. It is a recombinant human monoclonal antibody designed to specifically bind to the epidermal growth factor receptor (EGFR) on the surface of cancer cells. Technetium (99mTc) arcitumomab is used to detect metastatic colorectal cancer in patients who have not responded to standard treatments. It is administered intravenously and binds to the EGFR on cancer cells. The technetium radiopharmaceutical is then taken up by the cancer cells and can be detected using gamma camera imaging. The use of Technetium (99mTc) arcitumomab can help to identify the presence of metastatic colorectal cancer, aiding in the staging of the disease and the selection of appropriate treatment.
Technetium (99mTc) arcitumomab, also known by the trade name CEA-Scan, was a radiopharmaceutical agent used for imaging colorectal cancers [1]. It's important to note that it is no longer marketed in the United States.
Here's a breakdown of key points about Technetium (99mTc) arcitumomab:
- Function: It helped doctors detect the presence, location, and extent of colorectal cancer, particularly in the liver, abdomen, and pelvis [1,2].
- Type of medication: Diagnostic radiopharmaceutical (immunoconjugate)
- How it's administered: It was injected intravenously into a vein [2].
Medical Use:
- Colorectal cancer imaging: Technetium (99mTc) arcitumomab targeted a protein called carcinoembryonic antigen (CEA), often elevated in colorectal cancers. By binding to CEA, the radiotracer helped visualize these tumors during imaging scans [1,2].
Components:
- Technetium (99mTc): This is a radioactive isotope commonly used in nuclear medicine imaging for its safe and effective properties [2].
- Arcitumomab: This is a fragment of a monoclonal antibody specifically designed to target CEA [2].